Loren Gragert

Jun 13, 2024 | medrxiv.org | Michal A. Mankowski |Loren Gragert |Robert Montgomery |Dorry Segev

The authors have declared no competing interest. This study did not receive any fundingI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of NYU Langone gave ethical approval for this work.

Apr 21, 2023 | nature.com | Jonas Nilsson |Saghar Kaabinejadian |Hooman Yari |Carolina Barra |Loren Gragert

AbstractHuman leukocyte antigen (HLA) class II antigen presentation is key for controlling and triggering T cell immune responses. HLA-DQ molecules, which are believed to play a major role in autoimmune diseases, are heterodimers that can be formed as both cis and trans variants depending on whether the α- and β-chains are encoded on the same (cis) or opposite (trans) chromosomes. So far, limited progress has been made for predicting HLA-DQ antigen presentation.